Nova Scotia Health Authority
nshealth.caTotal trials
257
Active
89
Phase 3
15
Total enrollment
63,191
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 21 of 21 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Fleet Enema | — | — | — | — | — | 1 | |
| Pico-Salax | — | — | — | — | — | 1 | |
| Mepivacaine | — | — | — | — | — | 1 | |
| Chloroprocaine | — | — | — | — | — | 1 | |
| Metformin | — | — | — | — | — | 1 | |
| Pharmacotherapy | — | — | — | — | — | 1 | |
| Paritaprevir | — | — | — | — | — | 1 | |
| Ritonavir | — | — | — | — | — | 1 | |
| Dasabuvir | — | — | — | — | — | 1 | |
| Ombitasvir | — | — | — | — | — | 1 | |
| Ribavirin | — | — | — | — | — | 1 | |
| Lemborexant 5 MG | — | — | — | — | — | 1 | |
| Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery | — | — | — | — | — | 1 | |
| Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery | — | — | — | — | — | 1 | |
| Escitalopram | — | — | — | — | — | 1 | |
| Brexpiprazole | — | — | — | — | — | 1 | |
| Human Interleukin-2 | — | — | — | — | — | 1 | |
| Antidepressant medication | — | — | — | — | — | 1 | |
| Levothyroxine | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| Rate Control Medications | — | — | — | — | — | 1 |
Next readouts
- 2024-05-30
- 2025-10
- 2025-12-31
- 2026-06
- 2026-08-01
- 2026-08-31
- 2027-02
- 2027-04-04
- 2027-10
- 2028-04
Top conditions
- Stroke10
- Major Depressive Disorder7
- Frailty5
- Bipolar Disorder5
- Psychosis5
- Cancer4
- Osteoarthritis4
- Atrial Fibrillation4
Frequently asked questions about Nova Scotia Health Authority
- How many clinical trials does Nova Scotia Health Authority have on ClinicalTrials.gov?
- Nova Scotia Health Authority is listed as the lead sponsor on 257 clinical trials in ClinicalTrials.gov, 89 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Nova Scotia Health Authority's trials are in Phase 3?
- 15 of Nova Scotia Health Authority's trials are in Phase 3, spread across 21 active drug programs.
- What therapeutic areas does Nova Scotia Health Authority focus on?
- Nova Scotia Health Authority's most-studied conditions on ClinicalTrials.gov are Stroke, Major Depressive Disorder, Frailty, Bipolar Disorder, Psychosis.
- When are Nova Scotia Health Authority's next clinical trial readouts?
- Nova Scotia Health Authority has 10 upcoming primary-completion readouts tracked here; the soonest is “Personalization of Opioid Prescription Following Orthognathic Surgery”, expected around 2024-05-30.